Related Experiment Video
Updated: Aug 15, 2026
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062
1Department of Vascular Biology, Division of Cancer Control, Institute of Development, Aging and Cancer, Tohoku University, Seiryomachi, Sendai, Japan. k-hori@idac.tohoku.ac.jp
Abstract:
Despite extensive research efforts, effective therapies for refractive cancers have not yet been established, and development of successful treatment strategies remains the most important task in the field of oncology. We recently showed that AVE8062 (formerly AC7700), a derivative of combretastatin A-4, achieved irreversible stasis of tumor blood flow (TBF), thereby causing necrosis of tumor tissue by halting the supply of nutrients. Such effects were unrelated to cancer type. In this review, we summarize our experiments on antivascular and antitumor effects by AVE8062. We maintain that such starvation tactics against solid tumors constitute a new therapeutic strategy for all solid tumors, including refractory cancers.
Insights
AVE8062, a combretastatin A-4 derivative, halts tumor blood flow, causing necrosis. This antivascular strategy shows promise for treating refractory solid tumors by starving them of nutrients.
Area of Science:
- Oncology
- Vascular Biology
- Drug Development
Background:
- Refractory cancers lack effective therapies, necessitating novel treatment strategies.
- Tumor blood flow is crucial for nutrient supply and tumor growth.
- Targeting tumor vasculature offers a potential therapeutic approach.
Purpose of the Study:
- To review the antivascular and antitumor effects of AVE8062.
- To evaluate AVE8062 as a potential therapy for refractory solid tumors.
Main Methods:
- Administration of AVE8062, a combretastatin A-4 derivative.
- Assessment of tumor blood flow (TBF) and subsequent tumor necrosis.
- Evaluation of efficacy across different cancer types.
Main Results:
- AVE8062 induced irreversible stasis of tumor blood flow.
- This led to tumor tissue necrosis by halting nutrient supply.
- The antivascular effects were independent of cancer type.
Conclusions:
- AVE8062 demonstrates significant antivascular and antitumor activity.
- Starvation tactics targeting tumor vasculature represent a novel therapeutic strategy.
- AVE8062 holds potential for treating various solid tumors, including refractory cancers.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:24Regulation of Angiogenesis and Blood Supply
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...